摘要
目的:评价老年晚期肺腺癌患者接受培美曲塞(PEM)联合顺铂(DDP)方案化疗的疗效和不良反应。方法:年龄≥70岁初治的老年晚期肺腺癌患者共40例,接受PEM联合DDP方案化疗。PEM 500mg/m2静脉滴入,>10min,d1;DDP 20.0mg/m2静脉滴入,d1～d3。21d为1个周期。结果:共入组40例患者,均可评价疗效和不良反应。CR 0例,PR 17例,SD 16例,PD 7例,有效率为42.5%(17/40),中位疾病进展时间为6.5个月,中位生存期为12.8个月,1年生存率为56.8%。主要不良反应为白细胞下降(60.0%)、贫血(72.5%)、血小板下降(27.5%)、恶心呕吐(67.5%)、转氨酶升高(10.0%)、脱发(15.0%)及便秘(22.5%),未出现与化疗相关的死亡。结论:年龄≥70岁晚期肺腺癌患者可以耐受PEM联合DDP方案化疗的不良反应,并可以从中获益。
OBJECTIVE： To evaluate the efficacy and toxicity of pemetrexete（PEM） combined with cisplatin（DDP） in the first-line treatment for elderly advanced lung adenocarcinoma patients.METHODS： Forty patients more than 70 years old with advanced lung adenocarcinoma received pemetrexete combined with cisplatin regiment as first-line treatment： PEM 500 mg/m2,d1;DDP 20.0 mg/m2,d1-d3,every 21 days.RESULTS： All were evaluable for response.The overall response rate was 42.5%（0 CR,17 PR,16 SD,7 PD）.The median survival time（MST） was 12.8 months and 1 year survival rate was 56.8%.The most common toxicities were leucopenia（60.0%）,anemia（72.5%）,thrombocytopenia（27.5%）,nausea and vomiting（67.5%）,elevation of transaminase（10.0%）,alopecia（15.0%） and constipation（22.5%）.There were no treatment-related deaths.CONCLUSION： The elderly advanced lung adenocarcinoma patients can tolerate pemetrexete combined with cisplatin regiment and could get benefit from this regiment.
出处
《中华肿瘤防治杂志》
CAS
北大核心
2012年第4期297-299,共3页
Chinese Journal of Cancer Prevention and Treatment
基金
广东省卫生厅基金(B2009089)
关键词
癌
非小细胞肺/药物疗法
顺铂
培美曲塞
老年人
carcinoma
non-small cell lung/drug therapy
cisplatin
pemetrexete
elderly
